Regenerative medicine: Disrupting the status quo in 2021

By The Science Advisory Board staff writers

April 1, 2022 -- Regenerative medicine is taking aim at cancer and a wide range of other prevalent and rare diseases, according to the 2021 annual report of the Alliance for Regenerative Medicine (ARM).

"The exciting advancements of 2021 demonstrate that regenerative medicine is here -- and it's not slowing down," said Janet Lambert, CEO of ARM.

The #cellandgenetherapy sector disrupted the status quo in 2021 with new milestones, including the first proof-of-concept for an in vivo gene editing therapy, evidence that #CARTcell therapies compare favorably with earlier line treatments, and compelling early results that cell and gene therapies could durably treat complex, polygenic diseases.

ARM's 2021 annual report provides a comprehensive look into the investment, scientific, and clinical landscape. The 2021 report is ARM's most in-depth review of the sector to date, with never-before-released data including a deep dive into the oncology space, a look at prevalent versus #raredisease targets, an update on the #geneediting field, information on #genetherapy delivery, and more.

Read the report on ARM's site.

ARM update points to strong 2022 for cell and gene therapy industry
Despite a turbulent investment year, the cell and gene therapy space continued to innovate and develop at an extraordinary speed, according to the "Cell...
Catching up with the Alliance for Regenerative Medicine at Cell & Gene Meeting on the Mesa
CARLSBAD, CA - What's going on at this week's Cell & Gene Meeting on the Mesa? spoke with Stephen Majors, director of public...

Copyright © 2022

Last Updated bc 4/1/2022 7:24:55 AM